BioCryst Pharmaceuticals
biocryst.com · Healthcare · BCRX
Ranked 1,456 of 2,047 companies in the study
- Visibility0
- Citations0
- Sentiment50
- Site quality87
- AI readiness29
AI assistants do not name BioCryst Pharmaceuticals in any of their answers to market questions. Its overall score is 28 points out of 100, ranking 1,456th of 2,047 companies. The company's website passes 4 of 14 technical checks for readiness with AI tools.
We asked 15 unbranded questions about the healthcare market: none named BioCryst Pharmaceuticals. AI assistants named it in none of 60 answers. The typical healthcare company is named in 3.3% of answers. By how often it is named, BioCryst Pharmaceuticals ranks 69 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
The company is not named in this answer
“Which biotech pipelines show potential breakthroughs for the rare disease community?”
The biotech pipeline for rare diseases is experiencing a period of significant growth and innovation, driven by advancements in several key areas. These include gene therapy, CRISPR gene editing, and RNA-based therapeutics. The increased interest in rare diseases is also fueled by regulatory incentives and improved diagnostic tools.
1. Gene Therapy
Gene therapy aims to treat or cure diseases by correcting underlying genetic mutations. This can involve introducing, modifying, or repairing defective genes within a patient's cells to restore normal function. Rare genetic disorders, often ste …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPartly met
Serve an XML sitemap and reference it from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtPartly met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 29 of 100 · 97% of checks could run · checked on October 5, 2026 · www.biocryst.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- Not metXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Passedllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- Is it worth exploring newer rare disease therapies over established treatment options?
- What are the main differences between enzyme replacement therapy and RNA-based therapeutics for rare conditions?
- How do innovative biotech solutions help rare disease patients in the US?
- How are rare disease therapeutics typically priced in the US?
- Which biotech pipelines show potential breakthroughs for the rare disease community?
- How do gene therapies compare to small molecule treatments for rare diseases?
- What are the most promising new therapeutics for rare disease treatment?
- Are there non-pharmaceutical interventions available for rare disease management?
- How can caregivers support patients using advanced therapies for rare diseases?
- What are alternative therapeutic approaches for rare diseases when standard treatments are not effective?
- Do innovative rare disease treatments offer better outcomes than conventional approaches?
- What role do oral rare disease treatments play in managing chronic conditions?
- How can healthcare professionals address side effects from targeted rare disease therapeutics?
- What should patients do if rare disease symptoms don't improve with current biotech therapies?
- What financial assistance options exist for patients seeking innovative rare disease treatments?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.